Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olanzapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.98 |
| ▸ | DRD1 | P21728 | 5/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.98 |
| ▸ | HRH1 | P35367 | 5/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.98 |
| ▸ | HTR2B | P41595 | 5/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olanzapine SCHEMBL1376031 | 1.00 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL16114506 | 0.99 | CHRM1 (0.95) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1830363 | 0.99 | CHRM1 (0.95) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL28763 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL4775632 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29358280 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL6461808 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1562676 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL5091769 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | SYNPHATEC (SHANGHAI) BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-01 | — | — | US | claimed |
| CN-118169283-A | Detection method of fluoxetine impurity IV | 四川科瑞德制药股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| EP-4339189-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. (CN) | 2024-03-20 | — | — | EP | claimed |
| WO-2022237849-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | 中国科学院上海有机化学研究所 | 2022-11-17 | — | — | WO | claimed |
| US-20180169028-A1 | Nanoparticle Composition and Methods for Synthesis Thereof | ICEUTICA PTY LTD. (AU) | 2018-06-21 | — | — | US | claimed |
| EP-1830824-B1 | NANOPARTICLE COMPOSITION AND METHODS FOR SYNTHESIS THEREOF | ICEUTICA PTY LTD (AU) | 2016-01-13 | — | — | EP | claimed |
| JP-4763594-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| US-7951798-B2 | Polymorphs of olanzapine hydrochloride | Egis Hyogyszergyar Nyrt. (HU) | 2011-05-31 | — | — | US | claimed |
| EP-1620439-B1 | NEW POLYMORPHS OF OLANZAPINE HYDROCHLORIDE | EGIS GYOGYSZERGYAR NYRT (HU) | 2008-07-16 | — | — | EP | claimed |
| US-20070004706-A1 | New polymorphs of olanzapine hydrochloride | EGIS GYOGYSZERGYAR NYRT. (HU) | 2007-01-04 | — | — | US | claimed |
| JP-2006524219-A | — | — | 2006-10-26 | — | — | JP | claimed |
| WO-2006025065-A1 | A PROCESS FOR THE PREPARATION OF ANHYDROUS OLANZOPINE HYDROCHLORIDE OF FORM-1 | LEE PHARMA PRIVATE LIMITED (IN) | 2006-03-09 | — | — | WO | claimed |
| EP-1620439-A1 | NEW POLYMORPHS OF OLANZAPINE HYDROCHLORIDE | EGIS GYOGYSZERGYAR RT. (HU) | 2006-02-01 | — | — | EP | claimed |
| WO-2004094433-A1 | NEW POLYMORPHS OF OLANZAPINE HYDROCHLORIDE | EGIS Gyógyszergyár Rt. (HU) | 2004-11-04 | — | — | WO | claimed |
| US-20040067936-A1 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | REDDY'S LABORATORIES LIMITED (IN) | 2004-04-08 | — | — | US | claimed |
| EP-1313742-A1 | PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE | Dr. Reddy's Laboratories Ltd. (IN) | 2003-05-28 | — | — | EP | claimed |
| WO-2002018390-A1 | PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-03-07 | — | — | WO | claimed |
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | SYNPHATEC (SHANGHAI) BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| WO-2004094433-A1 | NEW POLYMORPHS OF OLANZAPINE HYDROCHLORIDE | EGIS Gyógyszergyár Rt. (HU) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094433-A1 | NEW POLYMORPHS OF OLANZAPINE HYDROCHLORIDE | EGIS Gyógyszergyár Rt. (HU) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169028-A1 | Nanoparticle Composition and Methods for Synthesis Thereof | CD47, CTTN, RHOA | DRD2 4779/4885HTR2A 4700/4885HTR2C 4806/4885 |
| US-20240254095-A1 | NMDA Receptor Antagonist and Use Thereof | GRIN2B, GRIN1, GRIN3A | DRD2 307/4885HTR2A 331/4885HTR2C 362/4885 |
| US-20070004706-A1 | New polymorphs of olanzapine hydrochloride | HTR1A, HTR3B, HTR3C | DRD2 56/4885HTR2A 15/4885HTR2C 6/4885 |
| US-20040067936-A1 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | CYP2F1, FIS1, CYP4B1 | DRD2 123/4885HTR2A 48/4885HTR2C 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.